Peptide Library

Human study PLS-00158

Thymosin ß4 expression in colorectal polyps and adenomas.

Cross-sectional study · Not reported participants enrolled · not included in the assessments (other)

Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Only the abstract was available. Essential methods may be missing, which limits what can be judged.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

  • Thymosin ß4 expression in colorectal polyps and adenomas.primary · Clinics (Sao Paulo, Brazil) · 2013-09-01 · PMID 24141838 · DOI

Design and participants

Design
Cross-sectional study
Population
Human intestinal biopsies: hyperplastic polyps, sessile serrated adenomas/polyps, colorectal adenomas with low- or high-grade dysplasia, adenocarcinomas and normal colon mucosa
Conditions
Colorectal polyps, Colorectal adenoma, Colorectal adenocarcinoma
Planned enrollment (registry)
Not reported
Enrolled
Not reported
Randomized
Not reported
Completed follow-up
Not reported

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

    What the authors reported

    As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

    Adverse events

    None reported. That is not evidence of safety, and how safety was monitored isn’t described.

    The authors concluded (paraphrased): Tβ4 is expressed at different steps of colon carcinogenesis. Its change in immunolocalization from low-grade to high-grade dysplasia suggests a role in colorectal carcinogenesis, but the meaning of this reactivity is unknown.

    Peptide Library’s assessment

    An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

    Limitations

    • other: The study measured endogenous Tβ4 in tissue by immunohistochemistry and gave no Tβ4 to anyone, so it gives no evidence on effects of administering the compound.
    • abstract only: Only the abstract is available in the record, so the methods and the full results cannot be appraised.
    • inappropriate endpoint: The only outcome is tissue immunoreactivity, a biomarker, with no clinical or safety outcomes.
    • no control group: The groups are descriptive tissue categories. No intervention or comparator was applied.
    • small or imprecise: Only 10 to 15 specimens per tissue category, and no statistical estimates are given in the abstract.

    No risk-of-bias assessment has been published for this study’s results.

    Claims this study informs

    Where each value comes from

    • author_conclusion: PMID 24141838, abstract (Conclusions, sentences 1-3) · extracted by AI (automated, not verified by a person) · abstract only
    • design: PMID 24141838, abstract (Methods, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only
    • limitations: PMID 24141838, abstract (Methods, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only
    • population: PMID 24141838, abstract (Methods, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only

    • Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

    These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).